68 related articles for article (PubMed ID: 38721084)
1. Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety.
La Torre G; Mannocci A; Colamesta V; D'Egidio V; Sestili C; Spadea A
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016044. PubMed ID: 27648207
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.
Das Barshan A; Matsumoto-Takahashi ELA
JMA J; 2024 Apr; 7(2):153-171. PubMed ID: 38721084
[TBL] [Abstract][Full Text] [Related]
3. Impact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research.
Nguyen LB; Vu LG; Le TT; Nguyen XT; Dao NG; Nguyen DC; Huyen Thi Dang T; Vu TMT; Boyer L; Fond G; Auquier P; Latkin CA; Zhang MWB; Ho RCM; Ho CSH
Health Qual Life Outcomes; 2023 Oct; 21(1):112. PubMed ID: 37821985
[TBL] [Abstract][Full Text] [Related]
4. Predicting Norovirus in England Using Existing and Emerging Syndromic Data: Infodemiology Study.
Ondrikova N; Harris JP; Douglas A; Hughes HE; Iturriza-Gomara M; Vivancos R; Elliot AJ; Cunliffe NA; Clough HE
J Med Internet Res; 2023 May; 25():e37540. PubMed ID: 37155231
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.
Kakkassery H; Carpenter E; Patten PEM; Irshad S
Trends Mol Med; 2022 Dec; 28(12):1082-1099. PubMed ID: 35999131
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
7. Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study.
Mair MJ; Berger JM; Mitterer M; Gansterer M; Bathke AC; Trutschnig W; Berghoff AS; Perkmann T; Haslacher H; Lamm WW; Raderer M; Tobudic S; Fuereder T; Buratti T; Fong D; Preusser M
Eur J Cancer; 2022 Apr; 165():184-194. PubMed ID: 35248840
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to COVID-19 vaccination in patients with lymphoma.
Narita K; Nakaji S; Tabata R; Terao T; Kuzume A; Tsushima T; Ikeda D; Fukumoto A; Miura D; Takeuchi M; Doi M; Umezawa Y; Otsuka Y; Takamatsu H; Matsue K
Int J Hematol; 2022 May; 115(5):728-736. PubMed ID: 35188650
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer.
Rugge M; Zorzi M; Guzzinati S
Nat Cancer; 2020 Aug; 1(8):784-788. PubMed ID: 35122051
[TBL] [Abstract][Full Text] [Related]
10. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
[TBL] [Abstract][Full Text] [Related]
11. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis.
Marra AR; Kobayashi T; Suzuki H; Alsuhaibani M; Tofaneto BM; Bariani LM; Auler MA; Salinas JL; Edmond MB; Doll M; Kutner JM; Pinho JRR; Rizzo LV; Miraglia JL; Schweizer ML
J Infect; 2022 Mar; 84(3):297-310. PubMed ID: 34982962
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP
Br J Haematol; 2022 Apr; 197(1):41-51. PubMed ID: 34962656
[TBL] [Abstract][Full Text] [Related]
13. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.
Teh JSK; Coussement J; Neoh ZCF; Spelman T; Lazarakis S; Slavin MA; Teh BW
Blood Adv; 2022 Apr; 6(7):2014-2034. PubMed ID: 34852173
[TBL] [Abstract][Full Text] [Related]
16. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
[TBL] [Abstract][Full Text] [Related]
18. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Aleman A; Upadhyaya B; Tuballes K; Kappes K; Gleason CR; Beach K; Agte S; Srivastava K; ; Van Oekelen O; Barcessat V; Bhardwaj N; Kim-Schulze S; Gnjatic S; Brown B; Cordon-Cardo C; Krammer F; Merad M; Jagannath S; Wajnberg A; Simon V; Parekh S
Cancer Cell; 2021 Nov; 39(11):1442-1444. PubMed ID: 34706273
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
